Expression of the Epstein-Barr virus protein LMP1 mediates tumor regression in vivo

Blood

Volumn 91, Issue 7, 1998, Pages 2491-2500

  Cherney, Barry W ^a   Sgadari, Cecilia ^b   Kanegane, Chiharu ^b   Wang, Frederick ^b   Tosato, Giovanna ^b  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ARTICLE; BURKITT LYMPHOMA; CELL IMMORTALIZATION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR BLOOD FLOW;

EID: 0032055162     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.7.2491.2491_2491_2500     Document Type: Article

References (46)

1. Rickinson A, Lee S, Steven N: Cytotoxic T lymphocyte responses to Epstein-Barr virus. Curr Opin Immunol 8:492, 1996
2. Tosato G, Taga K, Angiolillo AL, Sgadari C: Epstein-Barr virus as an agent of haematological disease, in Young NE (ed): Bailliere's Clinical Haematology. London, UK, Bailliere Tindall, 1995
3. Tosato G, Sgadari C, Taga K, Jones K, Pike S, Rosenberg A, Sechler JMG, Magrath IT, Bhatia K: Regression of experimental Burkitt's Lymphoma induced by Epstein-Barr Virus-immortalized human B cells. Blood 83:776, 1994
4. Angiolillo AL, Sgadari C, Sheikh N, Reaman GH, Tosato G: Regression of experimental human leukemias and solid tumors by Epstein-Barr Virus-immortalized B cells. Leuk Lymphoma 19:267, 1995
5. Sgadari C, Angiolillo AL, Cherney BW, Pike SE, Farber JM, Koniaris LG, Vanguri P, Burd PR, Sheikh N, Gupta G, Teruya-Feldstein J, Tosato G: Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci USA 93:13791, 1996
6. Sgadari C, Farber JM, Angiolillo AL, Fang L, Teruya-Feldstein J, Burd PR, Yao L, Gupta G, Kanegane C, Tosato G: Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 89:2635, 1997
7. Gurtsevitch VE, O'Connor GT, Lenoir GM: Burkitt's lymphoma cell lines reveal different degrees of tumorigenicity in nude mice. Int J Cancer 41:87, 1987
8. Wolf J, Draube A, Bohlen H, Jox A, Mucke S, Pawlita M, Moller P, Diehl V: Suppression of Burkitt's lymphoma tumorigenicity in nude mice by co-inoculation of EBV-immortalized lymphoblastoid cells. Int J Cancer 60:527, 1995
9. Luster A, Leder P: IP-10, a -C-X-C- chemokine, elicits a potent thymus dependent antitumor response in vivo. J Exp Med 181:1057, 1993
10. Arenberg DA, Kunkel SL, Polverini PJ, Morris SM, Burdick MD, Taub DT, Iannettoni MD, Whyte RI, Strieter RM: Interferongamma-inducible protein 10 (IP10) is an angiostatic factor that inhibits human non-same cell lung cancer (NSCLC) tumorigenesis and spontaneous metastasis. J Exp Med 184:981, 1996
11. Cherney B, Bhatia K, Sgadari S, Gutierrez MI, Mostowski H, Pike SE, Gupta G, Magrath IT, Tosato G: Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells. Cancer Res 57:2508, 1997
12. Magrath I, Erikson J, Whang-Peng J, Sieverts H, Armstrong G, Benjamin D, Triche T, Alabaster O, Croce C: Synthesis of kappa light chains by cell lines containing an 8;22 chromosomal translocation derived from a male homosexual with Burkitt's lymphoma. Science 222:1094, 1983
13. Gutierrez MI, Bhatia K, Cherney B, Capello D, Gaidano G, Magrath I: Interclonal molecular heterogeneity suggests a hierarchy of pathogenetic events in Burkitt's lymphoma. Ann Oncol 8:987, 1997
14. Cuomo L, Ramquist T, Trivedi P, Wang F, Klein G, Masucci MG: Expression of the Epstein-Barr virus (EBV)-encoded membrane protein LMP1 impairs the in vitro growth, clonability and tumorigenicity of an EBV-negative Burkitt lymphoma line. Int J Cancer 51:949, 1992
15. Kanegane H, Wang F, Tosato G: Virus-cell interactions in a natural killer-like cell line from a patient with lymphoblastic lymphoma. Blood 88:4667, 1996
16. Burd P, Thompson W, Max E, Mills F: Activated mast cells produce interleukin 13. J Exp Med 178:1373, 1995
17. Rowe M, Tooney CM, Edwards CF, Lenoir GM, Rupani H, Moss DH, Stein H, Epstein MA: Distinctions between endemic and sporadic forms of Epstein-Barr virus positive Burkitt's lymphoma. Int J Cancer 35:435, 1985
18. Liebowit D, Kieff E: Epstein-Barr virus. New York, NY, Raven, 1993
19. Zimber U, Adldinger HK, Lenoir GM, Vaillaume M, Knebel-Doeberitz MV, Laux G, Desgranges C, Wittmann P, Freese UK, Schneider U, Bornkamm GW: Geographical prevalence of two types of Epstein-Barr virus. Virol 154:56, 1986
20. Jones M, Foster L, Sheedy T, Griffin B: The EB virus genome in Daudi Burkitt lymphoma cells has a deletion similar to that observed in a non-transforming strain (P3HR-1) of the virus. EMBO J 3:813, 1984
21. Wang F, Tsang S, Kurilla M, Cohen J, Kieff E: Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol 64:3407, 1990
22. Hammerschmidt M, Sugden B, Baichwal VR: The transformation domain alone of the latent membrane protein of Epstein-Barr virus is toxic to cells when expressed at high levels. J Virol 63:2469, 1989
23. Martin JM, Veis D, Korsmeyer SJ, Sugden B: Latent membrane protein of Epstein-Barr virus induces cellular phenotypes independently of expression of Bcl-2. J Virol 67:5269, 1993
24. Floettmann JE, Ward K, Rickinson AB, Rowe M: Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-related expression in B cell lines. Virol 223:29, 1996
25. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longmecker R, Kieff E, Rickinson A: Induction of Bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65:1107, 1991
26. Rowe M, Peng-Pilon M, Huen DS, Hardy R, Croom-Carter D, Lundgren E, Rickinson AB: Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1 : A B-cell-specific response that is delayed relative to NF-κB activation and to induction of cell surface markers. J Virol 68:5602, 1994
27. Kaye KM, Izumi KM, Mosialos G, Kieff E: The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues. J Virol 69:675, 1995
28. Kaye KM, Devergne O, Harada JN, Izumi KM, Yalamanchili R, Kieff E, Mosialos G: Tumor necrosis factor receptor associated factor 2 is a mediator of NF-κB activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci USA 93:11085, 1996
29. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E: The Epstein-Barr Virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80:389, 1995
30. Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen MF, Kieff E, Mosialos G: Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-Lymphocyte transformation: Role in NF-κB activation. Mol Cell Biol 16:7098, 1996
31. Hennessy K, Fennewald S, Hummel M, Cole T, Kieff E: A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. Proc Natl Acad Sci USA 81:7201, 1984
32. Liebowitz D, Wang D, Kieff E: Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J Virol 58:233, 1986
33. Engelmann H, Holtmann H, Brakebusch C, Avni YS, Sarov I, Nophar Y, Hadas E, Leitner O, Wallach D: Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem 265:14497, 1990
34. Tartaglia LA, Goeddel DV: Tumor necrosis factor receptor signalling. A dominant negative mutation suppresses the activation of the 55-kDa tumor necrosis factor receptor. J Biol Chem 267:4304, 1992
35. Izumi KM, Kaye KM, Kieff ED: The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci USA 94:1447, 1997
36. Mitchell T, Sugden B: Stimulation of NF-kB-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J Virol 69:2968, 1995
37. Huen DS, Henderson SA, Croom-Carter D, Rowe M: The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10:549, 1995
38. Siebenlist U, Franzoso G, Brown K: Structure, regulation and function of NF-kB. Annu Rev Cell Biol 10:405, 1994
39. Liou HC, Baltimore D: Regulation of the NF-kB/rel transcription factor and IKB inhibitor system. Curr Opin Cell Biol 5:477, 1993
40. Wang F: Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 64:2309, 1990
41. Wang D, Liebowitz D, Wang F, Gregory D, Rickinson A, Larson R, Springer T, Kieff E: Epstein-Barr virus latent infection membrane protein alter the human B-lymphocyte phenotype: Deletion of the amino terminus abolishes activity. Virol 62:4173, 1988
42. Springer TA: Adhesion receptors of the immune system. Nature 346:425, 1990
43. Hynes RO: Integrins: Versatility, modulation and signaling in cell adhesion. Cell 69:11, 1992
44. Wang D, Liebowitz D, Kieff E: An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831, 1985
45. Jaffe E, Chan J, Su I, Frizzera G, Mon S, Feller A, Ho F: Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 20:103, 1996
46. Teruya-Feldstein J, Jaffe ES, Burd PR, Kanegane H, Kingma DW, Wilson WH, Longo DL, Tosato G: The role of Mig, the monokine induced by interferon-gamma, and IP-10, the interferon-gamma inducible protein 10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. Blood 90: 4099, 1997